vs

Side-by-side financial comparison of Emerald Holding, Inc. (EEX) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $132.7M, roughly 1.6× Emerald Holding, Inc.). Emerald Holding, Inc. runs the higher net margin — -22.8% vs -62.0%, a 39.3% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 24.3%). Emerald Holding, Inc. produced more free cash flow last quarter ($11.7M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -0.3%).

TVS Emerald Haven Realty Limited is an Indian real estate development company headquartered in Chennai, Tamil Nadu. A subsidiary of TVS Holdings, it specializes in sustainable residential communities and urban development projects.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

EEX vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.6× larger
RARE
$207.3M
$132.7M
EEX
Growing faster (revenue YoY)
RARE
RARE
+1.6% gap
RARE
25.9%
24.3%
EEX
Higher net margin
EEX
EEX
39.3% more per $
EEX
-22.8%
-62.0%
RARE
More free cash flow
EEX
EEX
$112.5M more FCF
EEX
$11.7M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-0.3%
EEX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
EEX
EEX
RARE
RARE
Revenue
$132.7M
$207.3M
Net Profit
$-30.2M
$-128.6M
Gross Margin
Operating Margin
-11.8%
-54.7%
Net Margin
-22.8%
-62.0%
Revenue YoY
24.3%
25.9%
Net Profit YoY
-692.2%
3.5%
EPS (diluted)
$-0.15
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EEX
EEX
RARE
RARE
Q4 25
$132.7M
$207.3M
Q3 25
$77.5M
$159.9M
Q2 25
$105.5M
$166.5M
Q1 25
$147.7M
$139.3M
Q4 24
$106.8M
$164.6M
Q3 24
$72.6M
$139.5M
Q2 24
$86.0M
$147.0M
Q1 24
$133.4M
$108.8M
Net Profit
EEX
EEX
RARE
RARE
Q4 25
$-30.2M
$-128.6M
Q3 25
$-14.4M
$-180.4M
Q2 25
$-1.4M
$-115.0M
Q1 25
$15.3M
$-151.1M
Q4 24
$5.1M
$-133.2M
Q3 24
$-11.1M
$-133.5M
Q2 24
$-2.8M
$-131.6M
Q1 24
$11.0M
$-170.7M
Operating Margin
EEX
EEX
RARE
RARE
Q4 25
-11.8%
-54.7%
Q3 25
-10.1%
-106.9%
Q2 25
9.7%
-64.8%
Q1 25
24.2%
-102.6%
Q4 24
19.5%
-74.3%
Q3 24
-6.5%
-94.6%
Q2 24
7.4%
-79.1%
Q1 24
18.2%
-151.9%
Net Margin
EEX
EEX
RARE
RARE
Q4 25
-22.8%
-62.0%
Q3 25
-18.6%
-112.8%
Q2 25
-1.3%
-69.0%
Q1 25
10.4%
-108.5%
Q4 24
4.8%
-80.9%
Q3 24
-15.3%
-95.7%
Q2 24
-3.3%
-89.5%
Q1 24
8.2%
-156.8%
EPS (diluted)
EEX
EEX
RARE
RARE
Q4 25
$-0.15
$-1.28
Q3 25
$-0.07
$-1.81
Q2 25
$-0.01
$-1.17
Q1 25
$0.08
$-1.57
Q4 24
$0.01
$-1.34
Q3 24
$-0.05
$-1.40
Q2 24
$-0.03
$-1.52
Q1 24
$0.00
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EEX
EEX
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$100.9M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.8M
$-80.0M
Total Assets
$1.2B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EEX
EEX
RARE
RARE
Q4 25
$100.9M
$421.0M
Q3 25
$95.4M
$202.5M
Q2 25
$156.4M
$176.3M
Q1 25
$276.8M
$127.1M
Q4 24
$194.8M
$174.0M
Q3 24
$188.9M
$150.6M
Q2 24
$193.2M
$480.7M
Q1 24
$186.8M
$112.3M
Stockholders' Equity
EEX
EEX
RARE
RARE
Q4 25
$338.8M
$-80.0M
Q3 25
$369.5M
$9.2M
Q2 25
$389.4M
$151.3M
Q1 25
$392.1M
$144.2M
Q4 24
$385.9M
$255.0M
Q3 24
$391.1M
$346.8M
Q2 24
$407.6M
$432.4M
Q1 24
$-90.7M
$140.3M
Total Assets
EEX
EEX
RARE
RARE
Q4 25
$1.2B
$1.5B
Q3 25
$1.2B
$1.2B
Q2 25
$1.2B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$1.0B
$1.5B
Q3 24
$1.1B
$1.5B
Q2 24
$1.1B
$1.6B
Q1 24
$1.1B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EEX
EEX
RARE
RARE
Operating Cash FlowLast quarter
$12.3M
$-99.8M
Free Cash FlowOCF − Capex
$11.7M
$-100.8M
FCF MarginFCF / Revenue
8.8%
-48.6%
Capex IntensityCapex / Revenue
0.5%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$41.4M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EEX
EEX
RARE
RARE
Q4 25
$12.3M
$-99.8M
Q3 25
$1.8M
$-91.4M
Q2 25
$15.9M
$-108.3M
Q1 25
$12.6M
$-166.5M
Q4 24
$20.6M
$-79.3M
Q3 24
$9.1M
$-67.0M
Q2 24
$9.8M
$-77.0M
Q1 24
$7.3M
$-190.7M
Free Cash Flow
EEX
EEX
RARE
RARE
Q4 25
$11.7M
$-100.8M
Q3 25
$1.5M
$-92.7M
Q2 25
$15.8M
$-110.7M
Q1 25
$12.4M
$-167.8M
Q4 24
$19.9M
$-79.5M
Q3 24
$9.0M
$-68.6M
Q2 24
$9.6M
$-79.0M
Q1 24
$7.0M
$-193.9M
FCF Margin
EEX
EEX
RARE
RARE
Q4 25
8.8%
-48.6%
Q3 25
1.9%
-58.0%
Q2 25
15.0%
-66.5%
Q1 25
8.4%
-120.5%
Q4 24
18.6%
-48.3%
Q3 24
12.4%
-49.2%
Q2 24
11.2%
-53.7%
Q1 24
5.2%
-178.2%
Capex Intensity
EEX
EEX
RARE
RARE
Q4 25
0.5%
0.5%
Q3 25
0.4%
0.8%
Q2 25
0.1%
1.5%
Q1 25
0.1%
1.0%
Q4 24
0.7%
0.1%
Q3 24
0.1%
1.2%
Q2 24
0.2%
1.4%
Q1 24
0.2%
3.0%
Cash Conversion
EEX
EEX
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
0.82×
Q4 24
4.04×
Q3 24
Q2 24
Q1 24
0.66×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EEX
EEX

Connections Segment$121.9M92%
Commerce Segment$5.5M4%
Content$5.3M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons